Denmark, Finland and Norway are the latest European countries to withdraw from sale certain OTC ranitidine-based drugs following a worldwide alert over the ingredient’s safety.
National regulators in the three Nordic countries have withdrawn from sale all OTC and prescription versions of ranitidine in response to findings by the European Medicines Agency and US Food and Drug Administration that certain presentations of the drug were contaminated with NDMA, a probable human carcinogen
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?